Corey Hopkins, PhD


Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986125 Nebraska Medical Center
Omaha, NE 68198-6125
402-559-9729 (Office)
Curriculum Vitae
Lab website

Teaching Activities:
Dr. Hopkins lectures in Medicinal Chemistry and Drug Discovery.

Research Activities/Interests:  
Dr. Hopkins’ primary research interests are related to the design, synthesis and optimization of biologically active small molecules as in vivo probes, drug discovery lead compounds and preclinical candidates.  My recent research has focused on designing novel positive allosteric modulators related to numerous CNS-related therapeutic areas.  In addition, I have been interested in ion channels for kidney failure, kinase targets for rare and neglected diseases, including pediatric cancers and ion channels for insecticide resistant mosquitos relating to malaria and Zika.  Initial work here at UNMC will focus on developing novel chemical probes as: TRPC5 ion channel antagonists that protects the kidney filter, G protein-coupled inwardly-rectifying potassium channel (GIRK) activators as novel anxiolytics, novel Dopamine receptor 4 antagonists for L-DOPA-induced dyskinesia and addiction, and inhibitors of the AeKir1 ion channel that cause kidney failure in mosquitoes that carry malaria, West Nile virus, dengue and yellow fever and Zika.

Recent Publications:

  1. “Virtual screening and biological evaluation of PPARg antagonists as potential anti-prostate cancer agents”, Almahmoud, S.; Elix, C. C.; Jones, J. O.; Hopkins, C. R.; Vennerstrom, J. L.; Zhong, H. A.* Bioorg. Med. Chem. 202146, 116368. DOI: 10.1016/j.bmc.2021.116368. 
  2. “Further synthesis and biological characterization of a series of 2-sulfonamidebenzamides as allosteric modulators of MrgX1”, Sharma, S.; Peng, Q.;Vadukoot, A. K.;Aretz, C.; Jensen, A. A.; Wallick, A. I.; Dong, X.; Hopkins, C. R.* ChemRxiv 2021, DOI: 3374/chemrxiv-2021-7cq5k. 
  3. “Discovery, synthesis and biological characterization of a series ofN-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers asnovel GIRK1/2 potassium channel activators”, Sharma, S.; Lesiak, L.; Aretz, C. D.; Du, Y.; Kumar, S.; Gautam, N.; Alnouti, Y.; Dhuria, N. V.; Chhonker, Y. S.; Weaver, C. D.; Hopkins, C. R.* RSC Med. Chem. 202112, 1366-1373. DOI: 10.1039/d1md00129a. RSC Special Issue on Chemical Probes. 
  4. “PIK3C3 Inhibition promotes sensitivity to colon cancer therapy by inhibiting cancer stem cells”, Kumar, B.; Ahmad, R.; Sharma, S.;Gowrikumar, S.;Primeaux, M.; Rana, S.; Natarajan, A.; Oupicky, D.; Hopkins, C. R.; Dhawan, P.; Singh, A. B.* Cancers 202113, 2168. Manuscript ID: DOI: 10.3390/cancers13092168. 
  5. “Further SAR on the (phenylsulfonyl)piperazine scaffold as inhibitors of theAedes aegyptiKir1 (AeKir) channel and larvicides”, Aretz, C. D.; Kharade, S. V.; Chronister, K.; Trigueros, R. R.; Rodriguez, E. J.; Piermarini, P. M.; Denton, J. S.; Hopkins, C. R.* ChemMedChem202116, 319-327. DOI: 10.1002/cmdc.202000598.  
  6. “Synthesis and SAR studies of 1H-pyrrolo[2,3-b]pyridine-2-carboxamides as phosphodiesterase 4B (PDE4B) inhibitors”,Vadukoot, A. K.; Sharma, S.;Aretz, C. D.; Kumar, S.; Gautam, N.; Alnouti, Y.; Aldrich, A. L.; Heim, C. E.; Kielian, T.; Hopkins, C. R.*  ACS Med. Chem. Lett. 202011, 1848-1854. DOI: 10.1021/acsmedchemlett.9b00369.  
  7. “Design, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridin-3-ylquinolines as activin-like kinase (ALK) inhibitors”,Engers, D. W.; Bollinger, S. R.; Felts, A. S.;Vadukoot, A. K.; Williams, C.; Blobaum, A. L.; Lindsley, C. W.; Hong, C. C.; Hopkins, C. R.* Bioorg. Med. Chem. Lett. 202030, 127418. DOI: 10.1016/j.bmcl.2020.127418.  
  8. “KVA-D-88, a novel preferable phosphodiesterase 4B inhibitor, decreases cocaine-mediated reward propertiesin vivo”,Burkovetskaya, M. E.; Liu, Q.; Vadukoot, A. K.; Gautam, N.; Alnouti, Y.; Kumar, S.; Miczek, K. A.; Buch, S.; Hopkins, C. R.*; Guo, M.-L.* ACS Chem. Neurosci. 202011, 2231-2242. DOI: 10.1021/acschemneuro.0c00170.    
  9. “Discovery and characterization of 2-nitro-5-(4-(phenylsulfonyl)piperazin-1-yl)-N-(pyridine4ylmethyl)anilines as novel inhibitors of theAedes aegypti(AeKir1) channel”, Aretz, C. D.; Morwitzer, M. J.; Sanford, A. G.; Hogan, A. M.; Portillo, M. V.; Kharade,  V.; Kramer, M.; McCarthey, J. B.; Trigueros, R. R.; Piermarini, P. M.; Denton, J. S.; Hopkins, C. R.* ACS Infect. Dis. 20195, 917-931. DOI: 10.1021/acsinfecdis.8b00368. 
  10. “Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2(5aryl-2H-tetrazol-2-yl)acetamidesas novel GIRK1/2 potassium channel activators", Sharma, S.;Kozek, K. A.; Abney, K. K.; Kumar, S.; Gautum, N.; Alnouti, Y.; Weaver, C. D.; Hopkins, C. R.* Bioorg. Med. Chem. Lett. 2019, 29, 791-796.  DOI: 10.1016/j.bmcl.2019.01.027.